NEUP Fundamental Analysis - NEUPHORIA THERAPEUTICS INC

Fundamental Rating

NEUP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While NEUP seems to be doing ok healthwise, there are quite some concerns on its profitability. NEUP has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NEUP has reported negative net income.

In the past year NEUP had a positive cash flow from operations.

NEUP had negative earnings in each of the past 5 years.

NEUP had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

NEUP's Return On Assets of -1.29% is amongst the best of the industry. NEUP outperforms 88.95% of its industry peers.

NEUP has a better Return On Equity (-1.95%) than 90.45% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1.29%
ROE	-1.95%
ROIC	N/A

ROA(3y)-44.06%

ROA(5y)-36.63%

ROE(3y)-62.56%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NEUP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.

NEUP has less shares outstanding than it did 1 year ago.

The number of shares outstanding for NEUP has been reduced compared to 5 years ago.

The debt/assets ratio for NEUP has been reduced compared to a year ago.

2.2 Solvency

NEUP has an Altman-Z score of -7.23. This is a bad value and indicates that NEUP is not financially healthy and even has some risk of bankruptcy.

NEUP's Altman-Z score of -7.23 is on the low side compared to the rest of the industry. NEUP is outperformed by 67.98% of its industry peers.

The Debt to FCF ratio of NEUP is 0.43, which is an excellent value as it means it would take NEUP, only 0.43 years of fcf income to pay off all of its debts.

The Debt to FCF ratio of NEUP (0.43) is better than 95.51% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that NEUP is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.00, NEUP perfoms like the industry average, outperforming 48.31% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0.43
Altman-Z	-7.23

ROIC/WACCN/A

WACC9.43%

2.3 Liquidity

NEUP has a Current Ratio of 3.56. This indicates that NEUP is financially healthy and has no problem in meeting its short term obligations.

NEUP has a Current ratio (3.56) which is in line with its industry peers.

A Quick Ratio of 3.56 indicates that NEUP has no problem at all paying its short term obligations.

With a Quick ratio value of 3.56, NEUP perfoms like the industry average, outperforming 43.45% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.56
Quick Ratio	3.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NEUP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -130.00%.

Measured over the past years, NEUP shows a very negative growth in Revenue. The Revenue has been decreasing by -59.98% on average per year.

EPS 1Y (TTM)-130%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4570%

Revenue 1Y (TTM)N/A

Revenue growth 3Y-33.45%

Revenue growth 5Y-59.98%

Sales Q2Q%N/A

3.2 Future

NEUP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -173.01% yearly.

Based on estimates for the next years, NEUP will show a quite strong growth in Revenue. The Revenue will grow by 14.87% on average per year.

EPS Next Y-104017.17%

EPS Next 2Y-3227.34%

EPS Next 3Y200.21%

EPS Next 5Y-173.01%

Revenue Next Year686792%

Revenue Next 2Y4405.1%

Revenue Next 3Y2711.32%

Revenue Next 5Y14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NEUP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NEUP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, NEUP is valued cheaper than 91.57% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	123.81
EV/EBITDA	N/A

4.3 Compensation for Growth

NEUP's earnings are expected to grow with 200.21% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-3227.34%

EPS Next 3Y200.21%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NEUP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUPHORIA THERAPEUTICS INC

NASDAQ:NEUP (10/23/2025, 8:20:47 PM)

After market: 4.38 +0.33 (+8.15%)

4.05

-0.25 (-5.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-29 2025-09-29/amc

Earnings (Next)N/A N/A

Inst Owners8.93%

Inst Owner Change-5.62%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap9.56M

Revenue(TTM)15.66M

Net Income(TTM)-370000

Analysts82.22

Price Target46.58 (1050.12%)

Short Float %1.57%

Short Ratio0.47

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)117.46%

EPS NQ rev (1m)-176.36%

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.61
P/FCF	123.81
P/OCF	123.81
P/B	0.5
P/tB	1.72
EV/EBITDA	N/A

EPS(TTM)-0.02

EYN/A

EPS(NY)-25.46

Fwd EYN/A

FCF(TTM)0.03

FCFY0.81%

OCF(TTM)0.03

OCFY0.81%

SpS6.64

BVpS8.05

TBVpS2.36

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.29%
ROE	-1.95%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	0.49%

ROA(3y)-44.06%

ROA(5y)-36.63%

ROE(3y)-62.56%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score7

Asset Turnover0.55

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0.43
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.56
Quick Ratio	3.56
Altman-Z	-7.23

F-Score7

WACC9.43%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-130%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4570%

EPS Next Y-104017.17%

EPS Next 2Y-3227.34%

EPS Next 3Y200.21%

EPS Next 5Y-173.01%

Revenue 1Y (TTM)N/A

Revenue growth 3Y-33.45%

Revenue growth 5Y-59.98%

Sales Q2Q%N/A

Revenue Next Year686792%

Revenue Next 2Y4405.1%

Revenue Next 3Y2711.32%

Revenue Next 5Y14.87%

EBIT growth 1Y93.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-238.74%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y100.53%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y100.53%

OCF growth 3YN/A

OCF growth 5YN/A

NEUPHORIA THERAPEUTICS INC (NEUP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens